ANN ARBOR, MICHIGAN
For as long as most people can remember, the public health message about body fat has been relentlessly one-directional: less is better, more is dangerous, and the road to a healthy metabolism runs through losing weight. A new study out of the University of Michigan, published this week, is quietly detonating that assumption. Researchers there have shown, in unusually granular detail, that losing the wrong kind of fat — or losing it in the wrong way — can be just as devastating to the body's metabolism as carrying too much of it. In some patients, it may be worse.
The findings, published in the Journal of Clinical Investigation and announced by Michigan Medicine on July 26, focus on a rare and brutal genetic condition called familial partial lipodystrophy type 2, or FPLD2. People with FPLD2 don't accumulate fat in the usual places — instead, their bodies progressively lose functional fat tissue from their arms, legs, and hips, often starting around puberty, while fat can pile up elsewhere, such as the face and neck. The visible result is a body that looks paradoxically lean or even muscular. The invisible result, doctors have long known, is some of the most severe insulin resistance and diabetes seen in any patient population, along with dangerously high triglycerides and a high risk of fatty liver disease. What nobody could fully explain was why. If fat is supposedly the problem, how can losing so much of it make things catastrophically worse?
A DOCTOR'S TWENTY-YEAR QUESTION, ANSWERED IN A MOUSE
Dr. Elif Oral, a clinician and professor in the University of Michigan's Division of Metabolism, Endocrinology and Diabetes, has spent much of her career treating patients with lipodystrophy syndromes and chasing this exact contradiction. Working alongside Ormond MacDougald, a professor of Molecular & Integrative Physiology, graduate researcher Jessica Maung, and a large multi-institution team, Oral set out to look inside diseased fat tissue itself — not just measure the damage from the outside, but watch, cell by cell, what actually happens as it fails.
To do it, the team engineered a mouse model in which they could switch off a specific gene, lamin A/C, exclusively inside fat cells. That gene is the same one mutated in human FPLD2 patients, making the mouse a close biological mirror of the disease. The researchers then compared what they saw in these engineered mice against fat tissue donated directly by human FPLD2 patients — a combination of animal modeling and real patient material that let them cross-check their findings against actual human disease rather than relying on mice alone.
What they found was not a single broken switch but a cascade of failures compounding on top of each other. "A simple explanation is that all of the fat cells (adipocytes) have really catastrophic things happening in them," said Maung, describing the scope of what the team observed. Gene activity inside the fat cells shifted dramatically, crippling their ability to properly process and store lipids — the basic job a fat cell exists to do. At the same time, both the fat cells themselves and the immune cells living within the fat tissue flipped into an aggressively pro-inflammatory state, essentially treating the tissue's own cells as a threat. And inside each cell, the mitochondria — the tiny structures that generate a cell's energy — stopped functioning normally, choking off the power supply the tissue needed to keep itself alive.
"All of these effects come together to create this perfect environment for the tissue to be really unhealthy and eventually disappear," Maung said.
WHY LOSING FAT TISSUE POISONS THE WHOLE BODY
It's the word "disappear" that carries the real weight of this discovery. Fat tissue, the researchers emphasize, is not simply an inert storage depot the body would be better off without — it is an active, essential organ, on par functionally with the liver or the pancreas, responsible for energy storage, hormone production, and metabolic regulation throughout the body. When healthy fat tissue is destroyed, as it is in FPLD2, the body loses its ability to manage circulating lipids and to release the metabolic hormones that keep blood sugar in balance. Those lipids and hormones don't just vanish along with the fat cells — they get redirected, often toward organs like the liver and pancreas that were never built to handle that load, setting the stage for fatty liver disease and severe insulin resistance.
"This is really underscoring the importance of healthy fats in keeping metabolism intact and functional," Oral said. "People think of Type 2 diabetes as a disease of beta cells, but it's actually a disease of fat cells, too." Beta cells, the insulin-producing cells inside the pancreas, have long been the central character in the diabetes story — it's their gradual failure that gets blamed for the disease in medical textbooks and public health messaging alike. Oral's comment reframes the picture: fat cells, this research shows, are not passive bystanders in that story. They're active participants in whether blood sugar controls hold or collapse, and their loss can drive diabetes just as surely as their excess can.
Because FPLD2 is a rare inherited disorder, only a relatively small number of patients worldwide are diagnosed with it, and it has historically received a fraction of the research funding aimed at more common, obesity-driven Type 2 diabetes. But the mechanism the Michigan team uncovered — inflammation, mitochondrial failure, and lipid-processing collapse converging to kill fat cells — is not unique to a rare genetic mutation. Similar cellular stress shows up, to different degrees, in far more common conditions: the partial lipodystrophy sometimes seen in patients on certain older HIV medications, in some autoimmune disorders, and even, some researchers now suspect, in localized pockets of unhealthy fat tissue within people who are technically overweight but whose fat cells have simply stopped working properly. Understanding the endpoint of total fat-cell failure in FPLD2 may end up illuminating milder versions of the same process happening quietly in far more people.
A NEW TARGET FOR TREATMENT
The practical payoff the researchers are chasing is a way to intervene before the damage becomes irreversible. Current treatment for lipodystrophy syndromes focuses mostly on managing the downstream consequences — insulin, cholesterol-lowering drugs, and in more severe cases, a synthetic version of the hormone leptin that lipodystrophy patients often lack. None of those approaches protect the fat cells themselves. Oral, MacDougald, and their colleagues believe their findings point toward a different strategy entirely: identifying drugs or interventions that could interrupt the inflammatory cascade or shore up mitochondrial function inside stressed fat cells early enough to keep the tissue alive, rather than simply treating the metabolic wreckage after it disappears.
That's a meaningfully different approach from most current diabetes drug development, which overwhelmingly targets the pancreas, the liver, or the gut hormones involved in appetite and insulin release — the pathways behind blockbuster drugs like the GLP-1 class of medications that have dominated headlines and pharmacy shelves for the past several years. A fat-cell-protective drug would be attacking the disease from an entirely different angle, one that has been comparatively under-explored precisely because fat loss, rather than fat gain, seemed like such an unlikely villain.
MacDougald was emphatic about crediting the collaborative, patient-centered nature of the work. "I think this work is an outstanding example of a collaboration between a translational clinical researcher and a basic science physiologist," he said. "We also can't overstate the importance of the patient population and their involvement in developing therapies and their dedication to understanding their disease." The human tissue samples that anchored the study, in other words, came from real FPLD2 patients who volunteered their own diseased fat for researchers to dissect and study — a detail easy to gloss over, but one that underlines how rare-disease research often depends on the willingness of a small, tightly connected patient community to participate directly in the science.
EXPERT PERSPECTIVE
The Michigan findings arrive at a moment when the broader endocrinology field has been steadily revising its view of adipose tissue's role in disease, following earlier 2026 research suggesting obesity itself may be better understood as fat tissue losing its normal function rather than simply accumulating in excess. Taken together, these lines of research are converging on a more nuanced picture: it isn't the amount of fat tissue in the body that matters most for metabolic health, but whether that fat tissue is functioning properly — storing lipids efficiently, signaling hormonally in a balanced way, and staying free of chronic inflammation. Too much dysfunctional fat causes disease. Too little functional fat causes disease. The common thread is dysfunction, not size.
WHAT THIS MEANS FOR YOU
You almost certainly don't have FPLD2 — it's a rare disease, and most people reading this will never personally encounter it. But the underlying lesson reaches much further than the rare-disease clinic. If you or someone you know has ever been told their diabetes or fatty liver "doesn't make sense" for their body type or weight, this research offers a partial explanation: metabolic disease isn't governed purely by how much fat someone carries, but by whether their fat tissue is doing its job. It's also a reminder that popular narratives around weight, fat, and health are often flatter and less accurate than the underlying biology — and that dramatic weight loss, whatever the cause, is not automatically a metabolic win if the fat tissue being lost was still functioning. For patients on medications or with conditions known to cause localized fat loss, this study is a signal that doctors may need to start monitoring metabolic health more closely, not less, when fat visibly disappears.
THE BOTTOM LINE
For decades, the fight against diabetes has been framed almost entirely as a fight against too much fat. The University of Michigan's new research doesn't overturn that framework so much as it completes it, revealing a mirror-image danger that hides in plain sight: fat tissue that inflames itself, poisons its own energy supply, and disappears — taking the body's metabolic stability down with it. As Dr. Oral put it, diabetes has never been just a disease of the pancreas. It's a disease of fat, too — whether there's too much of it, or, as this study proves, not nearly enough of the kind that's actually working.
